Evidence map›Paper›PMID 36126099›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2022

TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets

Cixiang Zhou, Difei Wang, Jingchi Li, Qiuyu Wang, Lulu Wo, Xin Zhang, Zhexuan Hu, Zheng Wang, Mengna Zhan, Ming He and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 68 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. METTL3-mediated SNHG1 mFrontiers in oncology · 2025
    Article
  15. Article
  16. Article
  17. Long non-coding RNAs: Key regulators of stemness in breast cancer.Frontiers in cell and developmental biology · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Cixiang ZhouState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Difei WangState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0001-7263-6401
Jingchi LiState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0001-6239-4111
Qiuyu WangState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Lulu WoState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Xin ZhangState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zhexuan HuState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Zheng WangDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Mengna ZhanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200031, China.
Ming HeState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Guohong HuChinese Academy of Sciences Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Xiaosong ChenDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Kunwei ShenDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0002-1961-8666
Guo-Qiang ChenState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0003-4936-2363
Qian ZhaoState Key Lab of Oncogene and Related Genes, Renji Hospital, Shanghai Institute of Cancer, Key Lab of Cell Differentiation and Apoptosis of Ministry of Education, Research Unit 2019RU043, Chinese Academy of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.ORCID 0000-0001-8103-8251
Shanghai Jiao Tong University · CNShanghai Institute of Nutrition and Health · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype for its high rates of relapse, great metastatic potential, and short overall survival. How cancer cells acquire metastatic potency through the conversion of noncancer stem-like cells into cancer cells with stem-cell properties is poorly understood. Here, we identified the long noncoding RNA (lncRNA) TGFB2-AS1 as an important regulator of the reversibility and plasticity of noncancer stem cell populations in TNBC. We revealed that TGFB2-AS1 impairs the breast cancer stem-like cell (BCSC) traits of TNBC cells in vitro and dramatically decreases tumorigenic frequency and lung metastasis in vivo. Mechanistically, TGFB2-AS1 interacts with SMARCA4, a core subunit of the SWI/SNF chromatin remodeling complex, and results in transcriptional repression of its target genes including

Indexed as

Lung NeoplasmsRNA, Long NoncodingTriple Negative Breast NeoplasmsAnimalsDNA HelicasesHumansMiceNeoplasm Recurrence, LocalNuclear ProteinsSOXB1 Transcription FactorsTranscription FactorsTransforming Growth Factor beta2DNA HelicasesNuclear ProteinsRNA, Long NoncodingSMARCA4 protein, humanSOX2 protein, humanSOXB1 Transcription FactorsTGFB2 protein, humanTranscription FactorsTransforming Growth Factor beta2cancer stem-like cellSWI/SNF complexTGFB2-AS1TGFβ signalingtriple-negative breast cancer

Identifiers

PMID36126099
PMCPMC9522332
OpenAlexW4296795192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.